279 related articles for article (PubMed ID: 37032137)
41. [Successful use of cladribine in the treatment of an elderly woman with typical hairy cell leukemia].
Terasaki Y; Okumura H; Hirose A; Ishiura Y; Yokawa S; Saito K; Nakao S
Gan To Kagaku Ryoho; 2007 Nov; 34(11):1885-8. PubMed ID: 18030031
[TBL] [Abstract][Full Text] [Related]
42. Combined treatment with splenectomy and cladribine in hairy cell leukemia in Taiwan: a clinicopathologic study of 5 cases.
Yu YB; Li CY; Chen CC; You JY; Chau WK; Hsu HC; Gau JP; Chen PM; Ho CH
J Chin Med Assoc; 2007 Dec; 70(12):551-5. PubMed ID: 18194897
[TBL] [Abstract][Full Text] [Related]
43. Long-Term Outcomes of Hairy Cell Leukemia Treated With Purine Analogs: A Comparison With the General Population.
Madanat YF; Rybicki L; Radivoyevitch T; Jagadeesh D; Dean R; Pohlman B; Kalaycio M; Sekeres MA; Smith MR; Hill BT
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):857-862. PubMed ID: 28778620
[TBL] [Abstract][Full Text] [Related]
44. Hairy Cell Leukemia: Retrospective Analysis of Demographic Data and Outcome of 203 Patients from 12 Medical Centers in Israel.
Inbar M; Herishanu Y; Goldschmidt N; Bairey O; Yuklea M; Shvidel L; Fineman R; Aviv A; Ruchlemer R; Braester A; Najib D; Rouvio O; Shaulov A; Greenbaum U; Polliack A; Tadmor T
Anticancer Res; 2018 Nov; 38(11):6423-6429. PubMed ID: 30396967
[TBL] [Abstract][Full Text] [Related]
45. Hairy cell leukemia: current concepts.
Cannon T; Mobarek D; Wegge J; Tabbara IA
Cancer Invest; 2008 Oct; 26(8):860-5. PubMed ID: 18798068
[TBL] [Abstract][Full Text] [Related]
46. Update on the biology and treatment options for hairy cell leukemia.
Jain P; Pemmaraju N; Ravandi F
Curr Treat Options Oncol; 2014 Jun; 15(2):187-209. PubMed ID: 24652320
[TBL] [Abstract][Full Text] [Related]
47. [Analysis of clinical and laboratory characteristics and survival with hairy cell leukemia].
Zhang YR; Wang YY; Li ZJ; Yi SH; Feng XY; Liu W; Qi JY; Zou DH; Zhao YZ; Qiu LG
Zhonghua Yi Xue Za Zhi; 2012 Dec; 92(46):3250-3. PubMed ID: 23328507
[TBL] [Abstract][Full Text] [Related]
48. Treatment of refractory hairy cell leukemia with a BRAF-inhibitor: lessons to be learnt.
Sári E; Nagy ZG; Baghy K; Rajnai H; Bödör C; Csomor J; Barna G; Rudas G; Kovalszky I; Demeter J
Pathol Oncol Res; 2014 Oct; 20(4):973-80. PubMed ID: 24789721
[TBL] [Abstract][Full Text] [Related]
49. Immunohistochemical analysis using a BRAF V600E mutation specific antibody is highly sensitive and specific for the diagnosis of hairy cell leukemia.
Wang XJ; Kim A; Li S
Int J Clin Exp Pathol; 2014; 7(7):4323-8. PubMed ID: 25120816
[TBL] [Abstract][Full Text] [Related]
50. How I manage patients with hairy cell leukaemia.
Thompson PA; Ravandi F
Br J Haematol; 2017 May; 177(4):543-556. PubMed ID: 28146266
[TBL] [Abstract][Full Text] [Related]
51. Identification of the BRAF V600E mutation in Japanese patients with hairy cell leukemia and related diseases using a quenching probe method.
Itamura H; Ide M; Sato A; Sueoka-Aragane N; Sueoka E; Nishida A; Masunari T; Aoki S; Takizawa J; Suzumiya J; Kimura S
Int J Hematol; 2018 Oct; 108(4):416-422. PubMed ID: 30043333
[TBL] [Abstract][Full Text] [Related]
52. Immunohistochemistry for BRAF V600E in the Differential Diagnosis of Hairy Cell Leukemia vs Other Splenic B-Cell Lymphomas.
Turakhia S; Lanigan C; Hamadeh F; Swerdlow SH; Tubbs RR; Cook JR
Am J Clin Pathol; 2015 Jul; 144(1):87-93. PubMed ID: 26071465
[TBL] [Abstract][Full Text] [Related]
53. Clinical features and diagnosis of hairy cell leukemia.
Quest GR; Johnston JB
Best Pract Res Clin Haematol; 2015 Dec; 28(4):180-92. PubMed ID: 26614896
[TBL] [Abstract][Full Text] [Related]
54. Long-term follow-up of patients with hairy cell leukemia in the south of Iran.
Dehghani M; Kashkooe A; Namdari N; Majidi R; Karimi M; Haghighat S; Rezvani A; Safari N
Expert Rev Hematol; 2023 Apr; 16(4):289-295. PubMed ID: 36709461
[TBL] [Abstract][Full Text] [Related]
55. Atypical presentation of hairy cell leukemia: Significance of CD200 on flow cytometry.
Rahman K; Kumari S; Singh MK; Gupta R; Yadav G; Kumari N; Nityan S
J Cancer Res Ther; 2018; 14(5):1130-1134. PubMed ID: 30197362
[TBL] [Abstract][Full Text] [Related]
56. BRAF(V600E) mutation in a histiocytic sarcoma arising from hairy cell leukemia.
Michonneau D; Kaltenbach S; Derrieux C; Trinquand A; Brouzes C; Gibault L; North MO; Delarue R; Varet B; Emile JF; Brousse N; Hermine O
J Clin Oncol; 2014 Dec; 32(35):e117-21. PubMed ID: 24567436
[No Abstract] [Full Text] [Related]
57. Flow cytometry of peripheral blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells, lymphocyte subsets and detection of minimal residual disease after treatment.
Babuŝíková O; Tomová A; Kusenda J; Gyárfás J
Neoplasma; 2001; 48(5):350-7. PubMed ID: 11845978
[TBL] [Abstract][Full Text] [Related]
58. Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study.
Pagano L; Criscuolo M; Broccoli A; Piciocchi A; Varettoni M; Galli E; Anastasia A; Cantonetti M; Trentin L; Kovalchuk S; Orsucci L; Frustaci A; Spolzino A; Volpetti S; Annibali O; Storti S; Stelitano C; Marchesi F; Offidani M; Casadei B; Nizzoli ME; De Luca ML; Fianchi L; Motta M; Guarnera L; Simonetti E; Visentin A; Vassallo F; Deodato M; Sarlo C; Olivieri A; Falini B; Pulsoni A; Tiacci E; Zinzani PL
Blood Cancer J; 2022 Jul; 12(7):109. PubMed ID: 35853850
[TBL] [Abstract][Full Text] [Related]
59. The diagnosis of hairy cell leukemia can be established by flow cytometric analysis of peripheral blood, even in patients with low levels of circulating malignant cells.
Cornfield DB; Mitchell Nelson DM; Rimsza LM; Moller-Patti D; Braylan RC
Am J Hematol; 2001 Aug; 67(4):223-6. PubMed ID: 11443633
[TBL] [Abstract][Full Text] [Related]
60. Cladribine in hairy cell leukemia.
Belani R; Saven A
Hematol Oncol Clin North Am; 2006 Oct; 20(5):1109-23. PubMed ID: 16990111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
